00:00It's Benzinga bringing Wall Street to Main Street.
00:02Merck beat third quarter estimates and raised its adjusted profit outlook on stronger than
00:07expected sales of its cancer treatment, Keytruda, including its newer injectable version,
00:12according to CNBC. The pharmaceutical giant reported third quarter adjusted earnings of
00:18$2.49 per share on revenue of $18.09 billion, beating analyst estimates of $2.08 per share
00:27and $17.31 billion, respectively. Merck's third quarter revenue rose 5% year-over-year
00:35to $18.09 billion, while Keytruda sales reached $8.60 billion, exceeding analyst expectations.
00:44The drug generated $8.60 billion in sales, including $830 million from its newer injectable
00:52version, Keytruda Culex. Merck raised its adjusted earnings outlook to $2.77 to $2.82 per share,
01:01from $2.66 to $2.76, and narrowed its 2026 revenue forecast to $66.8 billion to $67.3 billion.
01:13The company is working to transition patients to Keytruda Culex as key patents for the original
01:19treatment begin expiring in 2028. For all things money, visit Benzinga.com.
Comments